Status note AMPLIFY-7P Phase 2 failure reported June 2026; company evaluating pre-specified subgroups and refining Phase 3 strategy; no discontinuation disclosed.
ELI-002 2P
Phase 1 · ActiveModality: lymph node-targeted cancer immunotherapy (Amphiphile/AMP)
Target mKRAS
Partnerships MIT (license)
Indications
mKRAS-driven solid tumors (PDAC, CRC)(Phase 1)
Status note Studied in Phase 1 AMPLIFY-201; no discontinuation disclosed.
Status note Preclinical; no discontinuation disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.